BR112015008951A2 - composição de loção tópica de armazenamento estável, método para o tratamento de dermatoses responsivas a corticosteroides e método para a preparação da composição de loção tópica - Google Patents

composição de loção tópica de armazenamento estável, método para o tratamento de dermatoses responsivas a corticosteroides e método para a preparação da composição de loção tópica

Info

Publication number
BR112015008951A2
BR112015008951A2 BR112015008951A BR112015008951A BR112015008951A2 BR 112015008951 A2 BR112015008951 A2 BR 112015008951A2 BR 112015008951 A BR112015008951 A BR 112015008951A BR 112015008951 A BR112015008951 A BR 112015008951A BR 112015008951 A2 BR112015008951 A2 BR 112015008951A2
Authority
BR
Brazil
Prior art keywords
lotion composition
topical lotion
preparing
stable storage
responsive dermatoses
Prior art date
Application number
BR112015008951A
Other languages
English (en)
Portuguese (pt)
Inventor
F Popp Karl
A Johnson Keith
Original Assignee
Mical Pharmaceuticals Llc H Series
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50485547&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112015008951(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mical Pharmaceuticals Llc H Series filed Critical Mical Pharmaceuticals Llc H Series
Publication of BR112015008951A2 publication Critical patent/BR112015008951A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/16Emollients or protectives, e.g. against radiation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Toxicology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112015008951A 2012-10-18 2013-10-16 composição de loção tópica de armazenamento estável, método para o tratamento de dermatoses responsivas a corticosteroides e método para a preparação da composição de loção tópica BR112015008951A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261715467P 2012-10-18 2012-10-18
US13/921,859 US20140112959A1 (en) 2012-10-18 2013-06-19 Topical steroid composition and method
US13/921,833 US8962028B2 (en) 2012-10-18 2013-06-19 Topical steroid composition and method
PCT/US2013/065266 WO2014062817A1 (en) 2012-10-18 2013-10-16 Topical steroid composition and method

Publications (1)

Publication Number Publication Date
BR112015008951A2 true BR112015008951A2 (pt) 2017-07-04

Family

ID=50485547

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015008951A BR112015008951A2 (pt) 2012-10-18 2013-10-16 composição de loção tópica de armazenamento estável, método para o tratamento de dermatoses responsivas a corticosteroides e método para a preparação da composição de loção tópica

Country Status (19)

Country Link
US (3) US8962028B2 (https=)
EP (1) EP2919753A1 (https=)
JP (1) JP6385938B2 (https=)
KR (1) KR101832041B1 (https=)
CN (1) CN104884043B (https=)
AP (1) AP2015008420A0 (https=)
AU (1) AU2013331271B2 (https=)
BR (1) BR112015008951A2 (https=)
CA (1) CA2888853C (https=)
EA (1) EA029494B1 (https=)
IN (1) IN2015DN04160A (https=)
MX (1) MX371362B (https=)
MY (1) MY179354A (https=)
NZ (1) NZ706918A (https=)
PH (1) PH12015500859B1 (https=)
SG (1) SG11201502931YA (https=)
UA (1) UA115073C2 (https=)
WO (1) WO2014062817A1 (https=)
ZA (1) ZA201502692B (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11957753B2 (en) 2010-11-22 2024-04-16 Bausch Health Ireland Limited Pharmaceutical formulations containing corticosteroids for topical administration
US8809307B2 (en) 2010-11-22 2014-08-19 Dow Pharmaceutical Sciences, Inc. Pharmaceutical formulations containing corticosteroids for topical administration
CN108282998B (zh) 2015-06-18 2021-07-06 凡利亚药品北美公司 用于治疗银屑病的包含皮质类固醇和类视黄醇的局部组合物
US11311482B2 (en) 2017-05-12 2022-04-26 Bausch Health Us, Llc Topical compositions and methods for treating skin diseases
US12042487B2 (en) 2018-11-16 2024-07-23 Arcutis Biotherapeutics, Inc. Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US12011437B1 (en) 2017-06-07 2024-06-18 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
US11129818B2 (en) 2017-06-07 2021-09-28 Arcutis Biotherapeutics, Inc. Topical roflumilast formulation having improved delivery and plasma half life
US20210161870A1 (en) 2017-06-07 2021-06-03 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
US20200155524A1 (en) 2018-11-16 2020-05-21 Arcutis, Inc. Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US9895359B1 (en) 2017-06-07 2018-02-20 Arcutis, Inc. Inhibition of crystal growth of roflumilast
US11534382B2 (en) 2017-06-19 2022-12-27 Novan, Inc. Topical compositions and methods of using the same
JP7492918B2 (ja) 2018-06-04 2024-05-30 アーキュティス・バイオセラピューティクス・インコーポレーテッド ロフルミラスト皮膚浸透ラグタイムを改善する方法及び配合物
EP3937905A4 (en) 2019-03-14 2022-12-28 Crescita Therapeutics Inc. RINSING COMPOSITIONS AND THEIR USES FOR THE ADMINISTRATION OF ACTIVE AGENTS
CN109833291B (zh) * 2019-04-03 2022-08-26 普霖贝利生物医药研发(上海)有限公司 一种稳定的丙酸氯倍他索软膏及其制备方法
EP4458414A3 (en) 2020-12-04 2025-01-01 Arcutis Biotherapeutics, Inc. Topical roflumilast formulation having antifungal properties
CN118765194A (zh) 2021-12-28 2024-10-11 阿尔库缇斯生物疗法股份有限公司 局部罗氟司特气溶胶泡沫
EP4586999A1 (en) 2022-09-15 2025-07-23 Arcutis Biotherapeutics, Inc. Pharmaceutical compositions of roflumilast and solvents capable of dissolving high amounts of the drug
US12059430B2 (en) 2022-09-29 2024-08-13 Adora Animal Health Corporation Storage stable formulations of sulfated glycosaminoglycans and fragments derived therefrom for the treatment of pain and other medical conditions

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2655570A1 (de) 1975-12-12 1977-06-16 Ciba Geigy Ag Neue polyhalogensteroide und verfahren zu ihrer herstellung
DE3225848A1 (de) * 1982-07-07 1984-01-19 Schering AG, 1000 Berlin und 4709 Bergkamen Kortikoidhaltige zubereitung zur topischen applikation
US5064655A (en) 1989-02-24 1991-11-12 Liposome Technology, Inc. Liposome gel composition and method
US5219877A (en) 1989-09-25 1993-06-15 Bristol-Myers Squibb Company Lauryl alcohol as skin penetration enhancer for topical imidazole agents
US5326566A (en) 1991-05-17 1994-07-05 Bristol-Myers Squibb Company Use of dibutyl adipate and isopropyl myristate in topical and transdermal products
TW218849B (https=) * 1991-05-17 1994-01-11 Bristol Myers Squibb Co
CA2143515A1 (en) 1994-03-22 1995-09-23 Prakash Parab Method for enhancing the rate of skin permeation of lactic acid through use of the l-enantiomer
US6647058B1 (en) 1997-06-23 2003-11-11 Paradyne Corporation Performance customization system and process for optimizing XDSL performance
US6171985B1 (en) 1997-12-01 2001-01-09 3M Innovative Properties Company Low trauma adhesive article
US6673374B2 (en) 1998-07-31 2004-01-06 Howard Murad Pharmaceutical compositions and methods for managing skin conditions
US6315980B1 (en) 1998-09-25 2001-11-13 Shiseido Company, Ltd. Skin barrier function recovery and promotion composition and evaluation method thereof
WO2000040250A1 (fr) * 1999-01-06 2000-07-13 Taisho Pharmaceutical Co.,Ltd. Lotion a base d'amelometasone
US6495126B1 (en) 1999-07-20 2002-12-17 Mary Kay Inc. Treatment and composition for achieving skin anti-aging benefits by corneum protease activation
US6479058B1 (en) * 1999-09-02 2002-11-12 Mccadden Michael E. Composition for the topical treatment of poison ivy and other forms of contact dermatitis
US6656928B1 (en) 1999-09-02 2003-12-02 Mccadden Michael E. Composition for the topical treatment of rashes, dermatoses and lesions
US6967023B1 (en) 2000-01-10 2005-11-22 Foamix, Ltd. Pharmaceutical and cosmetic carrier or composition for topical application
US6756032B1 (en) 2000-07-12 2004-06-29 The Procter & Gamble Company Method to enhance and/or prolong the effects of a primary challenge to a responsive system with a secondary challenge
US6387383B1 (en) 2000-08-03 2002-05-14 Dow Pharmaceutical Sciences Topical low-viscosity gel composition
US6790203B2 (en) 2000-12-20 2004-09-14 Sca Hygiene Products Ab Absorbent product comprising leakage barriers
US6830758B2 (en) 2001-04-02 2004-12-14 Lectec Corporation Psoriasis patch
US6781027B2 (en) 2001-12-14 2004-08-24 Kimberly-Clark Worldwide, Inc. Mixed denier fluid management layers
US6765001B2 (en) 2001-12-21 2004-07-20 Medicis Pharmaceutical Corporation Compositions and methods for enhancing corticosteroid delivery
US7704518B2 (en) 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
US7208485B2 (en) 2003-01-13 2007-04-24 Chemagis Ltd. Crystalline forms of halobetasol propionate
US7186416B2 (en) 2003-05-28 2007-03-06 Stiefel Laboratories, Inc. Foamable pharmaceutical compositions and methods for treating a disorder
US8016811B2 (en) 2003-10-24 2011-09-13 Altea Therapeutics Corporation Method for transdermal delivery of permeant substances
CA2550811C (en) * 2003-12-24 2012-05-01 Jane Hirsh Temperature-stable formulations, and methods of development thereof
CN1942178A (zh) 2004-02-19 2007-04-04 奥克塞尔公司 用于治疗皮肤疾病的局部制剂
US20070189980A1 (en) 2004-06-07 2007-08-16 Jie Zhang Compositions and methods for treating alopecia
US8741333B2 (en) 2004-06-07 2014-06-03 Nuvo Research Inc. Compositions and methods for treating dermatitis or psoriasis
US20070196457A1 (en) 2004-06-07 2007-08-23 Jie Zhang Two or more volatile solvent-containing compositions and methods for dermal delivery of drugs
RU2438696C2 (ru) 2004-12-21 2012-01-10 Маск Фаундейшн Фор Рисерч Дивелопмент Композиции и способы, используемые для ускорения заживления ран и регенерации тканей
WO2006110534A2 (en) * 2005-04-07 2006-10-19 Taro Pharmaceuticals U.S.A., Inc. A process for preparing a crystalline form of halobetasol propionate
MX2009011493A (es) 2007-04-25 2009-11-09 Teva Pharma Complejo de excipiente farmaceutico.
RU2470645C2 (ru) * 2007-09-10 2012-12-27 Гленмарк Фармасьютикалс Лимитед Фармацевтическая композиция для местного применения, содержащая комбинацию фузидовой кислоты и кортикостероида
CH701253A1 (de) 2009-06-12 2010-12-15 Mibelle Ag Verwendung eines Extraktes aus Schneealgen in kosmetischen oder dermatologischen Formulierungen.
US8809307B2 (en) 2010-11-22 2014-08-19 Dow Pharmaceutical Sciences, Inc. Pharmaceutical formulations containing corticosteroids for topical administration

Also Published As

Publication number Publication date
CA2888853C (en) 2019-02-12
CA2888853A1 (en) 2014-04-24
AP2015008420A0 (en) 2015-05-31
US8962028B2 (en) 2015-02-24
MX371362B (es) 2020-01-27
CN104884043B (zh) 2018-12-11
US20140112991A1 (en) 2014-04-24
KR101832041B1 (ko) 2018-02-23
EA201590730A1 (ru) 2015-08-31
PH12015500859A1 (en) 2015-06-22
UA115073C2 (uk) 2017-09-11
MX2015004863A (es) 2016-02-05
MY179354A (en) 2020-11-04
NZ706918A (en) 2019-01-25
WO2014062817A1 (en) 2014-04-24
CN104884043A (zh) 2015-09-02
JP6385938B2 (ja) 2018-09-05
SG11201502931YA (en) 2015-05-28
KR20150069005A (ko) 2015-06-22
IN2015DN04160A (https=) 2015-10-16
US20140112959A1 (en) 2014-04-24
AU2013331271B2 (en) 2017-09-28
US20150119827A1 (en) 2015-04-30
JP2015534980A (ja) 2015-12-07
EP2919753A1 (en) 2015-09-23
ZA201502692B (en) 2016-01-27
PH12015500859B1 (en) 2015-06-22
EA029494B1 (ru) 2018-04-30
HK1214154A1 (zh) 2016-07-22
AU2013331271A1 (en) 2015-05-07

Similar Documents

Publication Publication Date Title
BR112015008951A2 (pt) composição de loção tópica de armazenamento estável, método para o tratamento de dermatoses responsivas a corticosteroides e método para a preparação da composição de loção tópica
BR112015006996A2 (pt) método para reduzir a quantidade de enxofre em uma composição que compreende enxofre, e, composição.
RS67779B1 (sr) Farmaceutska kompozicija, postupci za lečenje i njihova primena
EP3063163A4 (en) Nicotinamide riboside compositions for topical use in treating skin conditions
BR112013018679A2 (pt) agente para o tratamento da alopecia
EP3010487A4 (en) NON-AEROSOL FOAM FOR TOPICAL ADMINISTRATION
EP3035908A4 (en) Topical skin compositions for treating wrinkles
BR112014028723A2 (pt) forma cristalina, seu processo de produção e mistura, agente de proteção, uso da forma cristalina e método para o combate
BR112014027544A2 (pt) composição cosmética, processo cosmético e uso cosmético.
BR302012004626S1 (pt) "configuração aplicada em leitora para dispositivo móvel."
BR112014015135A2 (pt) polímero baseado em etileno, composição, artigo e processo para preparar o polímero baseado em etileno
BR112014031509A2 (pt) método in vitro para a determinação simultânea, conjunto e reômetro rotativo.
BR112014005422A2 (pt) suplemento de micronutriente, e, método para fazer o mesmo
BR112014031512A2 (pt) composição cosmética e método para o tratamento cosmético.
BR112014020545A2 (pt) composição aquosa tópica estável, processo para o preparo da composição aquosa tópica estável e método para o tratamento de acne
BR112014026873A2 (pt) método cosmético, composição cosmética e uso.
BR302012006416S1 (pt) Configuração aplicada em traquéia para dispositivos de inalação.
BR112015015040A2 (pt) composição sólida ou semissólida, método para a preparação da composição e utilização da composição
EP2981554A4 (en) Methods and compositions for treating and preventing disease associated with avb8 integrin
BR112014024415A2 (pt) “composição, processo para preparar a composição e método para controlar fungos fitopatogênicos”
BR112015005335A2 (pt) composição farmacêutica para tratar uma ferida, método para tratar uma ferida, composição farmacêutica contida em uma embalagem e kit para tratar uma ferida em um sujeito
EP3011336A4 (en) Methods, systems, and composition related to neural disorders
BR112014029232A2 (pt) composição cosmética, processo para preparar uma composição e processo cosmético
EP3072393A4 (en) Plant disease control agent, and plant disease control method
PT2793946T (pt) Composição tópica filmogénica e uso da mesma para tratar ou prevenir a onicofagia

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements